Mirati Therapeutics, Inc.
(NASDAQ : MRTX)

( )
MRTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
26.11%281.871.4%$749.34m
AMGNAmgen, Inc.
0.94%204.831.3%$389.48m
CELGCelgene Corp.
1.26%104.701.3%$375.89m
GILDGilead Sciences, Inc.
1.00%65.861.0%$371.46m
ILMNIllumina, Inc.
-1.52%309.053.5%$230.08m
VRTXVertex Pharmaceuticals, Inc.
4.10%191.061.9%$217.62m
REGNRegeneron Pharmaceuticals, Inc.
1.11%301.312.6%$207.80m
EXASEXACT Sciences Corp.
-4.25%88.8524.0%$175.92m
ALXNAlexion Pharmaceuticals, Inc.
-1.44%99.281.9%$169.24m
AAgilent Technologies, Inc.
-1.05%74.691.6%$132.10m
SGENSeattle Genetics, Inc.
-2.23%98.646.2%$130.55m
SRPTSarepta Therapeutics, Inc.
-1.24%85.5514.6%$127.16m
BMRNBioMarin Pharmaceutical, Inc.
-1.01%67.734.3%$95.03m
ALDRAlder Biopharmaceuticals, Inc.
-0.21%18.8810.2%$94.86m
NKTRNektar Therapeutics
-2.99%17.205.5%$82.10m

Company Profile

Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.